Search

Displaying results 841 - 850 of 4588 in total
  1. Drug

    Diphenoxylate

    go.drugbank.com/drugs/DB01081
    ApprovedIllicitInvestigational

    At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

  2. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.

  3. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options. … Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells.

  4. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    Both benign prostatic hyperplasia and androgenic alopecia are androgen-dependent disorders that are characterized by _in situ_ high levels of DHT. … [L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss.

  5. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

  6. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase

  7. Drug

    Pramocaine

    go.drugbank.com/drugs/DB09345
    Approved

    Pramocaine is available by itself and in combination with other medications in various topical preparations. … It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.

    Mixtures: Quality Choice Anti-Itch Clear, Quality Choice Anti-itch Medicated
  8. Drug

    Pixantrone

    go.drugbank.com/drugs/DB06193
    ApprovedWithdrawn

    It is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.

  9. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due to data quality

  10. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow.